Arrhythmias & electrophysiology
Feasibility, Efficacy, and Safety of Fluoroless Ablation of Ventricular Tachycardia (VT) in Patients With Structural Heart Disease
Authors' conclusion
Fluoroless ablation of VT in structural heart disease is feasible, effective, and safe when epicardial mapping/ablation is not required.
Study context
- Population
- Patients with ischemic and nonischemic cardiomyopathy undergoing VT ablation, excluding those requiring epicardial access or coronary angiography, 2017–202348% ischemic
- Participants
- 198 patients
- Outcome
- Freedom from VT recurrence
- Follow-up
- 22 ± 18 months
Methodological detailsconsecutive patients, single-group
- Consecutive patients
- Single-group
Main finding
As reported in the abstract
Freedom from VT recurrence
80%
Observational data: associations, not effects.
Further findings
Repeat ablation · follow-up 22 ± 18 months
- Patients undergoing repeat ablation
- 7.6%
Total procedural time
- Mean total procedural time
- 211 ± 70 minutes
Total radiofrequency time
- Total radiofrequency time
- 30 ± 22 minutes
Safety
- Procedure-related complications, 6 patients
- 3.0%
Original publication
Feasibility, Efficacy, and Safety of Fluoroless Ablation of VT in Patients With Structural Heart Disease. JACC Clin Electrophysiol. Published 29 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →